Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate whether the medication, febuxostat, can improve the
degree of insulin resistance and other features of the metabolic syndrome (high blood
pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol)
by lowering uric acid levels in the blood.